Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers
Objective To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recomme...
Gespeichert in:
| Veröffentlicht in: | Pediatric pulmonology 2012-05, Vol.47 (5), p.434-440 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 5 |
| container_start_page | 434 |
| container_title | Pediatric pulmonology |
| container_volume | 47 |
| creator | Glauser, T.A. Nevins, P.H. Williamson, J.C. Abdolrasulnia, M. Salinas, G.D. Zhang, J. Debonnett, L. Riekert, K.A. |
| description | Objective
To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied.
Methods
During Spring 2010, the CFF emailed survey invitations to directors of 136 accredited CF care centers treating 50+ CF patients. Directors were asked to forward the invitations to their physician colleagues. One hundred thirty‐three surveys were included in the analyses, representing 92 centers. Barriers were conceptualized based on Cabana et al.'s framework for adherence to guidelines. Adherence was assessed via a case vignette.
Results
Logistic regression analysis revealed that higher outcome expectancy (OR = 1.099, CI 1.010–1.196) and fewer environmental/system barriers (OR = 1.484, CI 1.158–1.902) were significantly associated with Vignette Adherence. A trend for an association between Familiarity and Vignette Adherence (OR = 1.642, CI 0.953–2.828) was evident, while no demographic variables were significantly associated with Vignette Adherence.
Conclusion
Targeting outcome expectancy and external barriers with multifaceted, ongoing interventions may improve guideline adherence. Pulmonologists are clearly looking for empirical evidence that these medications benefit their patients over the long‐term and offset patient treatment burden with improved health. Pediatr Pulmonol. 2012; 47:434–440. © 2012 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/ppul.21573 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1000407038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1000407038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3973-8f0252671bdb2e7437d8372ccb21959987bf45267a9e7884b95e2e1c0547e5213</originalsourceid><addsrcrecordid>eNp90M9P2zAUB3ALgaBju-wPmHxBQpPS-Uccx9xKt1K0inFYBTfjOC_DI02KnWz0v8elLdw4WbI_z--9L0KfKRlSQti35bKvh4wKyffQgBKlEpKqbB8NcilEkuUZP0IfQvhLSHxT9BAdMZYqoSQZoLtReQ8eGgu4a3F3D5gRIrFdhc5ZXLnCt8EFHDss2sb4Ff7TuxJq10A4wyPcmM7F-xqH3v-DFW4rPJ5gazxgC00HPnxEB5WpA3zansdoPvnxezxNZr8uLsejWWK5kjzJK8IEyyQtyoKBTLkscy6ZtQWjcVSVy6JK18AokHmeFkoAA2qJSCUIRvkxOt38u_TtYw-h0wsXLNS1aaDtg45JkZRIwvNIv26ojcsFD5VeereIy0W0dkyvE9UviUb8ZftvXyygfKW7CCM42QITrKkrbxrrwpsTUgnB1wPSjfvvali901JfX89nu-bJpsaFDp5ea4x_0JnkUuibqwutbr__vJrxqT7nz6Elm14</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1000407038</pqid></control><display><type>article</type><title>Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Glauser, T.A. ; Nevins, P.H. ; Williamson, J.C. ; Abdolrasulnia, M. ; Salinas, G.D. ; Zhang, J. ; Debonnett, L. ; Riekert, K.A.</creator><creatorcontrib>Glauser, T.A. ; Nevins, P.H. ; Williamson, J.C. ; Abdolrasulnia, M. ; Salinas, G.D. ; Zhang, J. ; Debonnett, L. ; Riekert, K.A.</creatorcontrib><description>Objective
To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied.
Methods
During Spring 2010, the CFF emailed survey invitations to directors of 136 accredited CF care centers treating 50+ CF patients. Directors were asked to forward the invitations to their physician colleagues. One hundred thirty‐three surveys were included in the analyses, representing 92 centers. Barriers were conceptualized based on Cabana et al.'s framework for adherence to guidelines. Adherence was assessed via a case vignette.
Results
Logistic regression analysis revealed that higher outcome expectancy (OR = 1.099, CI 1.010–1.196) and fewer environmental/system barriers (OR = 1.484, CI 1.158–1.902) were significantly associated with Vignette Adherence. A trend for an association between Familiarity and Vignette Adherence (OR = 1.642, CI 0.953–2.828) was evident, while no demographic variables were significantly associated with Vignette Adherence.
Conclusion
Targeting outcome expectancy and external barriers with multifaceted, ongoing interventions may improve guideline adherence. Pulmonologists are clearly looking for empirical evidence that these medications benefit their patients over the long‐term and offset patient treatment burden with improved health. Pediatr Pulmonol. 2012; 47:434–440. © 2012 Wiley Periodicals, Inc.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.21573</identifier><identifier>PMID: 22495970</identifier><identifier>CODEN: PEPUES</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>adherence ; Adolescent ; Adult ; Anti-Bacterial Agents - therapeutic use ; Attitude of Health Personnel ; Biological and medical sciences ; CF centers ; Child ; cystic fibrosis ; Cystic Fibrosis - complications ; Cystic Fibrosis - therapy ; Deoxyribonuclease I - therapeutic use ; Errors of metabolism ; Female ; General aspects ; Guideline Adherence - statistics & numerical data ; guidelines ; Health Care Surveys - statistics & numerical data ; Humans ; Macrolides - therapeutic use ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Miscellaneous hereditary metabolic disorders ; Pneumology ; Practice Guidelines as Topic ; Tobramycin - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Pediatric pulmonology, 2012-05, Vol.47 (5), p.434-440</ispartof><rights>Copyright © 2012 Wiley Periodicals, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3973-8f0252671bdb2e7437d8372ccb21959987bf45267a9e7884b95e2e1c0547e5213</citedby><cites>FETCH-LOGICAL-c3973-8f0252671bdb2e7437d8372ccb21959987bf45267a9e7884b95e2e1c0547e5213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fppul.21573$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fppul.21573$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25795531$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22495970$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glauser, T.A.</creatorcontrib><creatorcontrib>Nevins, P.H.</creatorcontrib><creatorcontrib>Williamson, J.C.</creatorcontrib><creatorcontrib>Abdolrasulnia, M.</creatorcontrib><creatorcontrib>Salinas, G.D.</creatorcontrib><creatorcontrib>Zhang, J.</creatorcontrib><creatorcontrib>Debonnett, L.</creatorcontrib><creatorcontrib>Riekert, K.A.</creatorcontrib><title>Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers</title><title>Pediatric pulmonology</title><addtitle>Pediatr. Pulmonol</addtitle><description>Objective
To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied.
Methods
During Spring 2010, the CFF emailed survey invitations to directors of 136 accredited CF care centers treating 50+ CF patients. Directors were asked to forward the invitations to their physician colleagues. One hundred thirty‐three surveys were included in the analyses, representing 92 centers. Barriers were conceptualized based on Cabana et al.'s framework for adherence to guidelines. Adherence was assessed via a case vignette.
Results
Logistic regression analysis revealed that higher outcome expectancy (OR = 1.099, CI 1.010–1.196) and fewer environmental/system barriers (OR = 1.484, CI 1.158–1.902) were significantly associated with Vignette Adherence. A trend for an association between Familiarity and Vignette Adherence (OR = 1.642, CI 0.953–2.828) was evident, while no demographic variables were significantly associated with Vignette Adherence.
Conclusion
Targeting outcome expectancy and external barriers with multifaceted, ongoing interventions may improve guideline adherence. Pulmonologists are clearly looking for empirical evidence that these medications benefit their patients over the long‐term and offset patient treatment burden with improved health. Pediatr Pulmonol. 2012; 47:434–440. © 2012 Wiley Periodicals, Inc.</description><subject>adherence</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Attitude of Health Personnel</subject><subject>Biological and medical sciences</subject><subject>CF centers</subject><subject>Child</subject><subject>cystic fibrosis</subject><subject>Cystic Fibrosis - complications</subject><subject>Cystic Fibrosis - therapy</subject><subject>Deoxyribonuclease I - therapeutic use</subject><subject>Errors of metabolism</subject><subject>Female</subject><subject>General aspects</subject><subject>Guideline Adherence - statistics & numerical data</subject><subject>guidelines</subject><subject>Health Care Surveys - statistics & numerical data</subject><subject>Humans</subject><subject>Macrolides - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous hereditary metabolic disorders</subject><subject>Pneumology</subject><subject>Practice Guidelines as Topic</subject><subject>Tobramycin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90M9P2zAUB3ALgaBju-wPmHxBQpPS-Uccx9xKt1K0inFYBTfjOC_DI02KnWz0v8elLdw4WbI_z--9L0KfKRlSQti35bKvh4wKyffQgBKlEpKqbB8NcilEkuUZP0IfQvhLSHxT9BAdMZYqoSQZoLtReQ8eGgu4a3F3D5gRIrFdhc5ZXLnCt8EFHDss2sb4Ff7TuxJq10A4wyPcmM7F-xqH3v-DFW4rPJ5gazxgC00HPnxEB5WpA3zansdoPvnxezxNZr8uLsejWWK5kjzJK8IEyyQtyoKBTLkscy6ZtQWjcVSVy6JK18AokHmeFkoAA2qJSCUIRvkxOt38u_TtYw-h0wsXLNS1aaDtg45JkZRIwvNIv26ojcsFD5VeereIy0W0dkyvE9UviUb8ZftvXyygfKW7CCM42QITrKkrbxrrwpsTUgnB1wPSjfvvali901JfX89nu-bJpsaFDp5ea4x_0JnkUuibqwutbr__vJrxqT7nz6Elm14</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Glauser, T.A.</creator><creator>Nevins, P.H.</creator><creator>Williamson, J.C.</creator><creator>Abdolrasulnia, M.</creator><creator>Salinas, G.D.</creator><creator>Zhang, J.</creator><creator>Debonnett, L.</creator><creator>Riekert, K.A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers</title><author>Glauser, T.A. ; Nevins, P.H. ; Williamson, J.C. ; Abdolrasulnia, M. ; Salinas, G.D. ; Zhang, J. ; Debonnett, L. ; Riekert, K.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3973-8f0252671bdb2e7437d8372ccb21959987bf45267a9e7884b95e2e1c0547e5213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>adherence</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Attitude of Health Personnel</topic><topic>Biological and medical sciences</topic><topic>CF centers</topic><topic>Child</topic><topic>cystic fibrosis</topic><topic>Cystic Fibrosis - complications</topic><topic>Cystic Fibrosis - therapy</topic><topic>Deoxyribonuclease I - therapeutic use</topic><topic>Errors of metabolism</topic><topic>Female</topic><topic>General aspects</topic><topic>Guideline Adherence - statistics & numerical data</topic><topic>guidelines</topic><topic>Health Care Surveys - statistics & numerical data</topic><topic>Humans</topic><topic>Macrolides - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous hereditary metabolic disorders</topic><topic>Pneumology</topic><topic>Practice Guidelines as Topic</topic><topic>Tobramycin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glauser, T.A.</creatorcontrib><creatorcontrib>Nevins, P.H.</creatorcontrib><creatorcontrib>Williamson, J.C.</creatorcontrib><creatorcontrib>Abdolrasulnia, M.</creatorcontrib><creatorcontrib>Salinas, G.D.</creatorcontrib><creatorcontrib>Zhang, J.</creatorcontrib><creatorcontrib>Debonnett, L.</creatorcontrib><creatorcontrib>Riekert, K.A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glauser, T.A.</au><au>Nevins, P.H.</au><au>Williamson, J.C.</au><au>Abdolrasulnia, M.</au><au>Salinas, G.D.</au><au>Zhang, J.</au><au>Debonnett, L.</au><au>Riekert, K.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr. Pulmonol</addtitle><date>2012-05</date><risdate>2012</risdate><volume>47</volume><issue>5</issue><spage>434</spage><epage>440</epage><pages>434-440</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><coden>PEPUES</coden><abstract>Objective
To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied.
Methods
During Spring 2010, the CFF emailed survey invitations to directors of 136 accredited CF care centers treating 50+ CF patients. Directors were asked to forward the invitations to their physician colleagues. One hundred thirty‐three surveys were included in the analyses, representing 92 centers. Barriers were conceptualized based on Cabana et al.'s framework for adherence to guidelines. Adherence was assessed via a case vignette.
Results
Logistic regression analysis revealed that higher outcome expectancy (OR = 1.099, CI 1.010–1.196) and fewer environmental/system barriers (OR = 1.484, CI 1.158–1.902) were significantly associated with Vignette Adherence. A trend for an association between Familiarity and Vignette Adherence (OR = 1.642, CI 0.953–2.828) was evident, while no demographic variables were significantly associated with Vignette Adherence.
Conclusion
Targeting outcome expectancy and external barriers with multifaceted, ongoing interventions may improve guideline adherence. Pulmonologists are clearly looking for empirical evidence that these medications benefit their patients over the long‐term and offset patient treatment burden with improved health. Pediatr Pulmonol. 2012; 47:434–440. © 2012 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22495970</pmid><doi>10.1002/ppul.21573</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8755-6863 |
| ispartof | Pediatric pulmonology, 2012-05, Vol.47 (5), p.434-440 |
| issn | 8755-6863 1099-0496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1000407038 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | adherence Adolescent Adult Anti-Bacterial Agents - therapeutic use Attitude of Health Personnel Biological and medical sciences CF centers Child cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - therapy Deoxyribonuclease I - therapeutic use Errors of metabolism Female General aspects Guideline Adherence - statistics & numerical data guidelines Health Care Surveys - statistics & numerical data Humans Macrolides - therapeutic use Male Medical sciences Metabolic diseases Middle Aged Miscellaneous hereditary metabolic disorders Pneumology Practice Guidelines as Topic Tobramycin - therapeutic use Treatment Outcome Young Adult |
| title | Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A35%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20the%202007%20cystic%20fibrosis%20pulmonary%20guidelines:%20A%20national%20survey%20of%20CF%20care%20centers&rft.jtitle=Pediatric%20pulmonology&rft.au=Glauser,%20T.A.&rft.date=2012-05&rft.volume=47&rft.issue=5&rft.spage=434&rft.epage=440&rft.pages=434-440&rft.issn=8755-6863&rft.eissn=1099-0496&rft.coden=PEPUES&rft_id=info:doi/10.1002/ppul.21573&rft_dat=%3Cproquest_cross%3E1000407038%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1000407038&rft_id=info:pmid/22495970&rfr_iscdi=true |